Development of 2,4-diaminopyrimidine derivatives as novel SNSR4 antagonists

Malken Bayrakdarian; Joanne Butterworth; Yun-Jin Hu; Vijayaratnam Santhakumar; Mirosław J Tomaszewski

doi:10.1016/j.bmcl.2011.01.138

Development of 2,4-diaminopyrimidine derivatives as novel SNSR4 antagonists

Bioorg Med Chem Lett. 2011 Apr 1;21(7):2102-5. doi: 10.1016/j.bmcl.2011.01.138. Epub 2011 Feb 3.

Authors

Malken Bayrakdarian¹, Joanne Butterworth, Yun-Jin Hu, Vijayaratnam Santhakumar, Mirosław J Tomaszewski

Affiliation

¹ Department of Medicinal Chemistry, AstraZeneca R&D Montreal, 7171 Frederick-Banting, Montréal, Québec, Canada H4S 1Z9.

PMID: 21333534
DOI: 10.1016/j.bmcl.2011.01.138

Abstract

2,4-Diaminopyrimidines derivatives were developed as a novel class of SNSR4 antagonists. Structure activity relationship of the diamino pyrimidine core was explored and a tool compound suitable for target validation was identified.

MeSH terms

Inhibitory Concentration 50
Pyrimidines / pharmacology*
Receptors, Cell Surface / antagonists & inhibitors*
Sensory Receptor Cells / drug effects*
Sensory Receptor Cells / metabolism

Substances

Pyrimidines
Receptors, Cell Surface
2,4-diaminopyrimidine